targeted therapy

(redirected from Targeted cancer therapy)

targeted therapy

A generic term for therapies that impact on a specific molecular pathway, target or ligand.

Examples
Gefitimib for non-small cell carcinoma of the lungs with mutations in epidermal growth factor receptor, and imatinib for GIST tumours with activating mutations in c-Kit.
References in periodicals archive ?
ENPNewswire-September 2, 2019--VAXIL BIO LICENSES P-ESBP FOR TARGETED CANCER THERAPY FROM BGN TECHNOLOGIES, THE TECHNOLOGY TRANSFER COMPANY OF BEN-GURION UNIVERSITY, ISRAEL
The company reported that it achieved statistically significant top-line results in a study evaluating crofelemer for treatment of diarrhea related to targeted cancer therapy.
The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance.
M2 EQUITYBITES-November 29, 2018-Quest PharmaTech and OncoCare Therapeutics to develop targeted cancer therapy technology for pancreatic cancer in the US
Global Banking News-November 29, 2018-Quest PharmaTech and OncoCare Therapeutics to develop targeted cancer therapy technology for pancreatic cancer in the US
M2 PHARMA-November 29, 2018-Quest PharmaTech and OncoCare Therapeutics to develop targeted cancer therapy technology for pancreatic cancer in the US
Barry Stoddard, a Fred Hutch protein engineer, got involved in a research project to modify a protein from yeast for possible use as part of a targeted cancer therapy. The modified protein was the brainchild of Washington State University biologist Margaret Black, who recognized that, with a few tweaks, this natural molecule could have potent anti-tumor power.
Handbook of Targeted Cancer Therapy and Immunotherapy, 2nd Edition (online access included)
"We have developed the first fully autonomous, DNA robotic system for a very precise drug design and targeted cancer therapy," said Hao Yan, director of the ASU Biodesign Institute's Center for Molecular Design and Biomimetics and the Milton Glick Professor in the School of Molecular Sciences.
"As the industry leader in ADCs, we bring deep expertise in targeted cancer therapy development to this collaboration with Pieris," said Dennis Benjamin, Ph.D., Senior Vice President of Research at Seattle Genetics.
In the article, "An Overview of Targeted Cancer Therapy," it states: "Targeted therapy is gaining importance due to its specificity towards cancer cells while sparing toxicity to off-target cells.
Early detection of preexisting drug resistance enables more personalized use of targeted cancer therapy. It also allows us to identify drugs that will serve no benefit and thus avoid unwanted side effects.

Full browser ?